Abstract
Aims: Fas ligand (FasL) expression by cancer cells may mediate tumour immune privilege. The purpose of the present study was to investigate the timing and significance of FasL expression during the colorectal adenoma-carcinoma sequence. Methods: FasL expression was studied by immunohistochemistry in 170 formalin-fixed tissue sections representing the entire colorectal adenoma-carcinoma sequence. Reverse transcriptase polymerase chain reaction (RT-PCR) was used to search for FasL mRNA. Analysis of survival was performed in patients with carcinomas. Results: A significant positive linear correlation was found between FasL expression and tumour progression throughout the colorectal adenoma-carcinoma sequence (rs=0.677; P
Original language | English |
---|---|
Pages (from-to) | 120-125 |
Number of pages | 6 |
Journal | European Journal of Surgical Oncology |
Volume | 28 |
Issue number | 2 |
DOIs | |
Publication status | Published - Mar 2002 |
Keywords
- Adenoma-carcinoma sequence
- Colorectal cancer
- Fas ligand
ASJC Scopus subject areas
- Oncology
- Surgery